{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:44:45Z","timestamp":1790995485442,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"DOI":"10.7759\/cureus.67891","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T08:08:40Z","timestamp":1724746120000},"source":"Crossref","is-referenced-by-count":9,"title":["A Review of the Regulatory Challenges of Personalized Medicine"],"prefix":"10.7759","author":[{"given":"Dharani","family":"S","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaraj","family":"R","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Personalized medicine and the practice of medicine in the 21st century","volume":"10","author":"Issa AM","year":"2007","unstructured":"Issa AM. Personalized medicine and the practice of medicine in the 21st century. Mcgill J Med. 2007, 10:53-7.","journal-title":"Mcgill J Med"},{"key":"ref2","article-title":"Personalized medicine: an overview","volume":"10","author":"Mishra V","year":"2019","unstructured":"Mishra V, Chanda P, Tambuwala MM, Suttee A. Personalized medicine: an overview. Int J Pharma Qual Assurance. 2019, 10:290-4.","journal-title":"Int J Pharma Qual Assurance"},{"key":"ref3","article-title":"Integrative Neuroscience and Personalized Medicine","year":"2010","unstructured":"Integrative Neuroscience and Personalized Medicine. Gordon E, Koslow SH (ed). Oxford University Press, New York City; 2010."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/jpm2010001","article-title":"Personalized medicine and cancer","volume":"2","author":"Verma M","year":"2012","unstructured":"Verma M. Personalized medicine and cancer. J Pers Med. 2012, 2:1-14. 10.3390\/jpm2010001","journal-title":"J Pers Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13030380","article-title":"Personalised medicine-implementation to the healthcare system in Europe (focus group discussions)","volume":"13","author":"Stefanicka-Wojtas D","year":"2023","unstructured":"Stefanicka-Wojtas D, Kurpas D. Personalised medicine-implementation to the healthcare system in Europe (focus group discussions). J Pers Med. 2023, 13:10.3390\/jpm13030380","journal-title":"J Pers Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.22377\/ajp.v12i01.2034","article-title":"Precision medicine in cancer treatment: an update","volume":"12","author":"Vyas DM","year":"2018","unstructured":"Vyas DM. Precision medicine in cancer treatment: an update. Asian J Pharma. 2018, 12:10.22377\/ajp.v12i01.2034","journal-title":"Asian J Pharma"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0453","article-title":"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib","volume":"66","author":"Carey KD","year":"2006","unstructured":"Carey KD, Garton AJ, Romero MS, et al.. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 2006, 66:8163-71. 10.1158\/0008-5472.CAN-06-0453","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00562.x","article-title":"Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression","volume":"98","author":"Wang H","year":"2007","unstructured":"Wang H, Yu J, Yang G, Song X, Sun X, Zhao S, Mu D. Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression. Cancer Sci. 2007, 98:1413-6. 10.1111\/j.1349-7006.2007.00562.x","journal-title":"Cancer Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.2799","article-title":"Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group","volume":"23","author":"Grundy PE","year":"2005","unstructured":"Grundy PE, Breslow NE, Li S, et al.. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005, 23:7312-21. 10.1200\/JCO.2005.01.2799","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group","volume":"61","author":"Weigel B","year":"2014","unstructured":"Weigel B, Malempati S, Reid JM, et al.. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014, 61:452-6. 10.1002\/pbc.24605","journal-title":"Pediatr Blood Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3601-1","article-title":"Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma","volume":"21","author":"Xu L","year":"2014","unstructured":"Xu L, Zhu Y, Chen L, et al.. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol. 2014, 21:3142-50. 10.1245\/s10434-014-3601-1","journal-title":"Ann Surg Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/ar2419","article-title":"Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept","volume":"10","author":"Koczan D","year":"2008","unstructured":"Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, Thiesen HJ. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther. 2008, 10:R50. 10.1186\/ar2419","journal-title":"Arthritis Res Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/ar1990","article-title":"Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis","volume":"8","author":"Lequerr\u00e9 T","year":"2006","unstructured":"Lequerr\u00e9 T, Gauthier-Jauneau AC, Bansard C, et al.. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther. 2006, 8:R105. 10.1186\/ar1990","journal-title":"Arthritis Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2217\/pme.10.53","article-title":"US FDA and personalized medicine: in vitro diagnostic regulatory perspective","volume":"7","author":"Te\u017eak \u017d","year":"2010","unstructured":"Te\u017eak \u017d, Kondratovich MV, Mansfield E. US FDA and personalized medicine: in vitro diagnostic regulatory perspective. Per Med. 2010, 7:517-30. 10.2217\/pme.10.53","journal-title":"Per Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrd771","article-title":"Ethical perspectives on pharmacogenomic profiling in the drug development process","volume":"1","author":"Issa AM","year":"2002","unstructured":"Issa AM. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat Rev Drug Discov. 2002, 1:300-8. 10.1038\/nrd771","journal-title":"Nat Rev Drug Discov"},{"key":"ref16","article-title":"Ethical considerations in clinical pharmacogenomics research","volume":"21","author":"Issa AM","year":"2000","unstructured":"Issa AM. Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol Sci. 2000, 21:247-9.","journal-title":"Trends Pharmacol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2018.05.006","article-title":"Personalized medicine: motivation, challenges, and progress","volume":"109","author":"Goetz LH","year":"2018","unstructured":"Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018, 109:952-63. 10.1016\/j.fertnstert.2018.05.006","journal-title":"Fertil Steril"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2013.40","article-title":"Pharmacogenetics of warfarin: challenges and opportunities","volume":"58","author":"Lee MT","year":"2013","unstructured":"Lee MT, Klein TE. Pharmacogenetics of warfarin: challenges and opportunities. J Hum Genet. 2013, 58:334-8. 10.1038\/jhg.2013.40","journal-title":"J Hum Genet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200011000-00013","article-title":"Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia","volume":"12","author":"O'Dwyer ME","year":"2000","unstructured":"O'Dwyer ME, Druker BJ. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol. 2000, 12:594-7. 10.1097\/00001622-200011000-00013","journal-title":"Curr Opin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281861-a-review-of-the-regulatory-challenges-of-personalized-medicine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T08:08:44Z","timestamp":1724746124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281861-a-review-of-the-regulatory-challenges-of-personalized-medicine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.67891","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}